Ascentis Independent Advisors Increases Position in Eli Lilly and Company $LLY

Ascentis Independent Advisors increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 110.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,432 shares of the company’s stock after buying an additional 3,897 shares during the quarter. Ascentis Independent Advisors’ holdings in Eli Lilly and Company were worth $6,837,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. LVZ Inc. increased its holdings in shares of Eli Lilly and Company by 1.5% in the first quarter. LVZ Inc. now owns 1,533 shares of the company’s stock valued at $1,410,000 after purchasing an additional 23 shares during the period. Raleigh Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 2.2% during the first quarter. Raleigh Capital Management Inc. now owns 1,735 shares of the company’s stock worth $1,596,000 after purchasing an additional 38 shares during the period. GM Advisory Group LLC grew its position in Eli Lilly and Company by 2.8% in the 1st quarter. GM Advisory Group LLC now owns 10,002 shares of the company’s stock valued at $9,199,000 after buying an additional 273 shares during the last quarter. Astoria Portfolio Advisors LLC. grew its position in Eli Lilly and Company by 3.5% in the 1st quarter. Astoria Portfolio Advisors LLC. now owns 1,841 shares of the company’s stock valued at $1,598,000 after buying an additional 62 shares during the last quarter. Finally, HBE Wealth Management LLC increased its stake in Eli Lilly and Company by 25.3% in the 1st quarter. HBE Wealth Management LLC now owns 292 shares of the company’s stock valued at $269,000 after buying an additional 59 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.1%

Shares of NYSE LLY opened at $1,200.89 on Tuesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,238.00. The firm’s 50 day moving average price is $1,065.45 and its 200 day moving average price is $1,027.90. The firm has a market cap of $1.13 trillion, a P/E ratio of 42.66, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 35.74 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Wolfe Research restated an “outperform” rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,239.52.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its R&D footprint through a new research collaboration with Abbisko Cayman Limited, which could help deepen its pipeline and support long-term growth. Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover
• Positive Sentiment: Investor sentiment remains supported by Lilly’s strong obesity and diabetes franchise, including continued enthusiasm around GLP-1 leadership, Medicare coverage momentum, and potential oral formulations that could broaden demand. Eli Lilly Stock (LLY) Opinions on Medicare Coverage and Drug Pipeline Advancements
• Neutral Sentiment: LLY remains one of the market’s most closely watched healthcare names, with multiple articles highlighting its premium valuation and ongoing debate about whether the stock can keep outperforming after a huge run-up. Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
• Negative Sentiment: Eli Lilly also faced pressure from regulatory and pricing-policy concerns, which were cited as a reason the shares slipped even as the broader market moved higher. Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges
• Negative Sentiment: Recent market wrap coverage noted that LLY declined while the market rose, suggesting some near-term profit-taking or valuation rotation after a strong advance. Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.